HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones

Cancer Immunology, Immunotherapy

Volumn 50, Issue 11, 2002, Pages 615-624

  Perez, Sonia A ^a   Sotiropoulou, Panagiota A ^a   Sotiriadou, Nectaria N ^a   Mamalaki, Avgi ^b   Gritzapis, Angelos D ^a   Echner, Hartmut ^c   Voelter, Wolfgang ^c   Pawelec, Graham ^d   Papamichail, Michael ^a   Baxevanis, Constantin N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Antigen presentation; Cancer patients; CD4+ T cell clones; HER 2 neu peptide; TCRBV phenotype

Indexed keywords

CD4 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN 100; HLA DR4 ANTIGEN; ONCOPROTEIN; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; BREAST ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MELANOMA CELL; MONONUCLEAR CELL; ONCOGENE NEU; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL LINE;

EID: 0035678918     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620100225     Document Type: Article

References (42)

1. + T cell responses
2. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides
3. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha
4. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
5. Help for cytotoxic-T cell responses is mediated by CD40 signaling
6. HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
7. + T lymphocytes
8. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2
9. Existent T-cells and antibody immunity to HER-2/neu protein in patients with breast cancer
10. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
11. In vitro generation of cytolytic T-cells specific for peptides derived from HER-2/neu proto-oncogene protein
12. Structural basis of specificity and degeneracy of T cell recognition: Pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T-cell receptor, peptide, and HLA-DR
13. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
14. Existent proliferative response of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides
15. The role of endosomes and lysosomes in MHC class II functioning
16. Novel class II-restricted melanoma antigens
17. + T cells in the antitumor immune response
18. Basic science of HER-2/neu: A review
19. + T lymphocytes following immunization with helper epitopes of HER-2/neu
20. Defining promiscuous MHC class II helper T-cell epitopes for HER-2/neu tumor antigen
21. + T cells in the absence of exogenous feeder cells
22. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer
23. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
24. Colorectal cancer vaccines
25. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
26. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
27. Cells and cytokines in immunotherapy and gene therapy of cancer
28. The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
29. + T-helper and a T-killer cell
30. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
31. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
32. + cytolytic T lymphocytes
33. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
34. CD4 T cells and their role in antitumor immune responses
35. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer
36. Human tumor antigens: Implications for cancer vaccine development
37. Human tumor antigens for cancer vaccine development
38. + T cell responses
39. Overexpression of HER-2/neu protooncogene in human pancreatic carcinoma
40. - T cell receptor-aβ phenotypes generated in CD8-depleted C57BL/6 mice
41. HER-2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
42. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses